Forest Bolsters its CNS Portfolio
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 55 (Table of Contents)
Published: 5 Jan-2005
DOI: 10.3833/pdr.v2005.i55.739 ISSN: 1756-7874
Section: General
Abstract
Forest Laboratories entered into an agreement with Gedeon Richter for Gedeon’s RGH-188, an orally active potent D2/D3 antagonist that has entered into phase 1 clinical trials...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS